We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-7.79%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.41B
AUM Growth
-$143M
Cap. Flow
+$78.9M
Cap. Flow %
5.61%
Top 10 Hldgs %
48.2%
Holding
246
New
54
Increased
32
Reduced
53
Closed
52

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$38M
2
FOLD
Amicus Therapeutics
FOLD
+$22M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$21.2M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.7M
5
ANIP icon
ANI Pharmaceuticals
ANIP
+$15.6M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$25.1M
2
DXCM icon
DexCom
DXCM
+$15.7M
3
AERI
Aerie Pharmaceuticals
AERI
+$13.5M
4
ASRT
Assertio
ASRT
+$13.4M
5
CRBP icon
Corbus Pharmaceuticals
CRBP
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.84%
2 Miscellaneous 1.6%
3 Consumer Staples 0.43%
4 Consumer Discretionary 0.07%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
126
Novavax
NVAX
$1.52B
$423K 0.03%
+16,771
New +$489K
SCMP
127
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$416K 0.03%
30,694
-10,402
-25% -$145K
MOH icon
128
Molina Healthcare
MOH
$10.8B
$379K 0.03%
6,981
-1,898
-21% -$104K
RACE icon
129
Ferrari
RACE
$71.5B
$360K 0.03%
6,200
– –
PZRX
130
DELISTED
PhaseRx, Inc.
PZRX
$310K 0.02%
200,000
– –
IRIX icon
131
IRIDEX
IRIX
$11.1M
$308K 0.02%
+21,885
New +$311K
AGEN
132
Agenus
AGEN
$322M
$297K 0.02%
3,678
-42,177
-92% -$4.14M
ALPN
133
DELISTED
Alpine Immune Sciences Inc
ALPN
$274K 0.02%
30,569
– –
SRPT icon
134
PUT
Sarepta Therapeutics
SRPT
$2.19B
$249K 0.02%
+10,900
New +$438K
GRCE
135
Grace Therapeutics
GRCE
$46.9M
$233K 0.02%
3,887
-1,041
-21% -$69.9K
PBYI icon
136
Puma Biotechnology
PBYI
$477M
$225K 0.02%
7,344
– –
LHCG
137
DELISTED
LHC Group LLC
LHCG
$217K 0.02%
4,745
– –
ENDP
138
DELISTED
Endo International plc
ENDP
$213K 0.02%
+12,920
New +$227K
MACK
139
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$200K 0.01%
6,216
– –
NTLA icon
140
Intellia Therapeutics
NTLA
$1.59B
$192K 0.01%
14,673
– –
ALR
141
DELISTED
AlerisLife Inc
ALR
$183K 0.01%
+6,780
New +$180K
GNVC
142
DELISTED
GenVec, Inc.
GNVC
$180K 0.01%
56,131
-1
-0% -$3
PMD
143
DELISTED
Psychemedics Corporation
PMD
$164K 0.01%
6,626
-6,000
-48% -$134K
BOLD
144
DELISTED
Audentes Therapeutics, Inc
BOLD
$137K 0.01%
7,500
– –
ONSIW
145
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$124K 0.01%
656,382
– –
STML
146
DELISTED
Stemline Therapeutics, Inc.
STML
$115K 0.01%
10,702
– –
CYNO
147
DELISTED
Cynosure, Inc. Class A
CYNO
$82K 0.01%
1,800
– –
CEMP
148
DELISTED
Cempra, Inc.
CEMP
$62K ﹤0.01%
22,321
-153,182
-87% -$1.86M
RXDX
149
DELISTED
Ignyta, Inc.
RXDX
$35K ﹤0.01%
6,584
-333,143
-98% -$1.94M
VCEL icon
150
Vericel Corp
VCEL
$2.03B
$28K ﹤0.01%
9,385
-535,611
-98% -$1.38M
4 5
6
7 8

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Perceptive Advisors held 246 positions worth $1.41B, down 9.2% from $1.55B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $78.9M of net new capital in Q4 2016, opening 54 new positions and adding to 32 existing holdings. Its largest new stake was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $25.1M trimmed.

  • Perceptive Advisors's largest Q4 2016 buy was Lakefront Biotherapeutics American Depositary Shares: 304,531 shares worth $20.6M.
  • Perceptive Advisors added most to Neurocrine Biosciences in Q4 2016, an estimated $38M increase.
  • Perceptive Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $25.1M.
  • Perceptive Advisors fully exited DexCom in Q4 2016, selling an estimated $15.7M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.41B portfolio in Q4 2016.
  • Perceptive Advisors opened 54 new positions and closed 52 in Q4 2016.
  • Perceptive Advisors's portfolio value fell 9.2% quarter-over-quarter to $1.41B.

Based on Perceptive Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.